Citation: yoon, sh.Md.Et al.Transcatheter mitral valve replacement for degenerated bioprosthetic valves and failed annuloplasty ringsj.Joutnal of the american college of cardiology.(2017) vol.70, no.9 doi 10.1016/j.Jacc.2017.07.714 earliest date of e-publish/publish used for event date.No unique device identifier (serial/lot) numbers were provided; without this information, it cannot be determined whether this event has been previously reported.(b)(4).
|
Medtronic received information via literature review regarding outcomes after a transcatheter mitral valve replacement (tmvr).All data were collected from a multi-center, multi-national registry between 2009 and 2017.The study population included 248 patients, all of which had a previously implant mitral annuloplasty ring, band or mitral bioprosthetic valve.Four patients were implanted valve-in-valve with a melody transcatheter bioprosthetic valve.Serial numbers were not provided.The study population was predominantly female; mean age 72.5 years.Among all patients adverse events included: conversion to surgery, left ventricular outflow tract (lvot) obstruction, valve dislodgement, the implant of a second valve, left ventricle perforation, thrombus, increased gradient measurements, and greater than moderate mitral regurgitation.Other adverse events included; reintervention due to paravalvular leak (pvl), atrial septal defect or surgical mitral replacement.Based on the available information, these events may have been attributed to a medtronic product.However as multiple manufacturers were noted in the literature, a direct correlation could not be made between the observed adverse events and the medtronic product.No additional adverse patient effects or product performance issues were reported.
|